Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Bayer discloses HIV protease inhibitors

Aug. 16, 1996

VX-478 covered under U.S. patent for HIV/AIDS

Aug. 9, 1996

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

GalaGen's Sporidin G enters phase II/III

Aug. 9, 1996

Immtech's r(m)CRP HIV treatment covered under U.S. patent

Aug. 9, 1996

Cel-Sci now holds full rights to HGP-30

Aug. 9, 1996

BioChem Pharma to challenge Epivir patent

Aug. 9, 1996

A-76202: Alpha-glucosidase/sucrase-isomaltase complex inhibitor from Sankyo

Aug. 9, 1996

Emory University files Epivir patent infringement action

Aug. 9, 1996

Study of Epivir's effect on HIV survival and disease progression terminated

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...